Alnylam partnered with GlaxoSmithKline to use Alnylam's VaxiRNA technology to increase virus titers during the production of GSK's vaccine products

Alnylam Pharmaceuticals Inc.

U.S. / Small-Cap Biopharma (<$1 billion)

$337.5m on 11/04/2011 [market cap]

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

GlaxoSmithKline plc

U.K. / Large-Cap Biopharma (>=$50 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced